Statistical issues in multisite effectiveness trials: the case of brief strategic family therapy for adolescent drug abuse treatment.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The statistical development of the multisite Brief Strategic Family Therapy (BSFT) Trial of the National Institute on Drug Abuse's Clinical Trials Network provides a useful, real example of how an effectiveness trial can differ from an efficacy trial. In particular, two design elements distinguish this effectiveness trial from an efficacy trial. First, because the goal of the trial is to show that the use of BSFT would be an improvement on current practice, it was decided to compare BSFT to treatment as usual at each location. This decision ensures that the trial has the most ecological validity to the participating community treatment providers. Second, the desire to generalize the results to general clinical practice dictates that variability (in effect) across community treatment providers be estimated using a random effects model. These two decisions jointly influence the sample size calculations. Allowing variation in treatment as usual, will increase the variability in effect sizes across sites and estimation of this variability as a random effect necessitates a larger sample size (both number of community treatment providers and participants per community treatment provider), than is the case for a fixed site effect estimate. Details of these effects and their implications for the statistical design are presented.

Original languageEnglish
Pages (from-to)428-439
Number of pages12
JournalClinical trials (London, England)
Volume1
Issue number5
StatePublished - Dec 1 2004

Fingerprint

Family Therapy
Substance-Related Disorders
Sample Size
National Institute on Drug Abuse (U.S.)
Therapeutics
General Practice
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b8008c955ce44d49b32ad838730e294c,
title = "Statistical issues in multisite effectiveness trials: the case of brief strategic family therapy for adolescent drug abuse treatment.",
abstract = "The statistical development of the multisite Brief Strategic Family Therapy (BSFT) Trial of the National Institute on Drug Abuse's Clinical Trials Network provides a useful, real example of how an effectiveness trial can differ from an efficacy trial. In particular, two design elements distinguish this effectiveness trial from an efficacy trial. First, because the goal of the trial is to show that the use of BSFT would be an improvement on current practice, it was decided to compare BSFT to treatment as usual at each location. This decision ensures that the trial has the most ecological validity to the participating community treatment providers. Second, the desire to generalize the results to general clinical practice dictates that variability (in effect) across community treatment providers be estimated using a random effects model. These two decisions jointly influence the sample size calculations. Allowing variation in treatment as usual, will increase the variability in effect sizes across sites and estimation of this variability as a random effect necessitates a larger sample size (both number of community treatment providers and participants per community treatment provider), than is the case for a fixed site effect estimate. Details of these effects and their implications for the statistical design are presented.",
author = "Feaster, {Daniel J} and Robbins, {Michael S.} and Viviana Horigian and Jose Szapocznik",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "428--439",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Statistical issues in multisite effectiveness trials

T2 - the case of brief strategic family therapy for adolescent drug abuse treatment.

AU - Feaster, Daniel J

AU - Robbins, Michael S.

AU - Horigian, Viviana

AU - Szapocznik, Jose

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The statistical development of the multisite Brief Strategic Family Therapy (BSFT) Trial of the National Institute on Drug Abuse's Clinical Trials Network provides a useful, real example of how an effectiveness trial can differ from an efficacy trial. In particular, two design elements distinguish this effectiveness trial from an efficacy trial. First, because the goal of the trial is to show that the use of BSFT would be an improvement on current practice, it was decided to compare BSFT to treatment as usual at each location. This decision ensures that the trial has the most ecological validity to the participating community treatment providers. Second, the desire to generalize the results to general clinical practice dictates that variability (in effect) across community treatment providers be estimated using a random effects model. These two decisions jointly influence the sample size calculations. Allowing variation in treatment as usual, will increase the variability in effect sizes across sites and estimation of this variability as a random effect necessitates a larger sample size (both number of community treatment providers and participants per community treatment provider), than is the case for a fixed site effect estimate. Details of these effects and their implications for the statistical design are presented.

AB - The statistical development of the multisite Brief Strategic Family Therapy (BSFT) Trial of the National Institute on Drug Abuse's Clinical Trials Network provides a useful, real example of how an effectiveness trial can differ from an efficacy trial. In particular, two design elements distinguish this effectiveness trial from an efficacy trial. First, because the goal of the trial is to show that the use of BSFT would be an improvement on current practice, it was decided to compare BSFT to treatment as usual at each location. This decision ensures that the trial has the most ecological validity to the participating community treatment providers. Second, the desire to generalize the results to general clinical practice dictates that variability (in effect) across community treatment providers be estimated using a random effects model. These two decisions jointly influence the sample size calculations. Allowing variation in treatment as usual, will increase the variability in effect sizes across sites and estimation of this variability as a random effect necessitates a larger sample size (both number of community treatment providers and participants per community treatment provider), than is the case for a fixed site effect estimate. Details of these effects and their implications for the statistical design are presented.

UR - http://www.scopus.com/inward/record.url?scp=33646339196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646339196&partnerID=8YFLogxK

M3 - Article

C2 - 16279281

AN - SCOPUS:33646339196

VL - 1

SP - 428

EP - 439

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 5

ER -